Vincent J Kidd, 69110 Plantation Woods Cv, Cordova, TN 38018
Vincent Kidd Phones & Addresses
110 Plantation Woods Cv, Cordova, TN 38018
131 Messina Woods Dr, Braintree, MA 02184
Birmingham, AL
Melrose, MA
Shiloh, TN
Houston, TX
Mentions for Vincent J Kidd
Publications & IP owners
Us Patents
Tumor Suppressor Protein Involved In Death Signaling, And Diagnostics, Therapeutics, And Screening Based On This Protein
US Patent:
7052834, May 30, 2006
Filed:
Dec 30, 1999
Appl. No.:
09/477082
Inventors:
Vincent J. Kidd - Memphis TN, US
Jill M. Lahti - Memphis TN, US
Tal Teitz - Cordova TN, US
Jill M. Lahti - Memphis TN, US
Tal Teitz - Cordova TN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12Q 1/68
C07H 21/04
C07H 21/04
US Classification:
435 6, 435 4, 436 63, 436 64, 536 241, 536 243, 536 2431, 536 2433
Abstract:
The present invention relates to identification of tumor suppressor activity of a protein, caspase-8 (CASP8), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter. In particular, CASP8 is functionally inactivated in greater than 90% of all MYCN amplified neuroblastoma cell lines analyzed. Inactivation of CASP8 was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. A PCR methylation analysis for inactivation of CASP8 is described.
Cyclin-C Variants, And Diagnostic And Therapeutic Uses Thereof
US Patent:
6075123, Jun 13, 2000
Filed:
Jun 2, 1997
Appl. No.:
8/867381
Inventors:
Jill M. Lahti - Cordova TN
Vincent J. Kidd - Cordova TN
Vincent J. Kidd - Cordova TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C07K 1700
C07H 2104
C12N 1500
C07H 2104
C12N 1500
US Classification:
530350
Abstract:
The present invention includes alternatively and partially spliced cyclin C mRNAs, recombinant DNA and the truncated protein (a truncated cyclin C) they encode. The alternatively spliced mRNAs result from an insertion of unique exons containing premature termination codons. The partially spliced mRNAs result from an insertion of additional coding sequence derived from exons. One aspect of the present invention is the demonstration that at least one of the alternatively spliced cyclin C mRNAs is produced in a cell cycle dependent fashion, as is the novel truncated cyclin box protein that it encodes. Truncated cyclin C acts as an endogenously encoded cyclin C inhibitor by negatively regulating cyclin C/cdk8 complex activity, in much the same way as the cyclin dependent protein kinase inhibitors that inhibit the D-type cyclins, cyclin A and cyclin E.
Cyclin-C Variants, And Diagnostic And Therapeutic Uses Thereof
US Patent:
6306648, Oct 23, 2001
Filed:
Mar 8, 2000
Appl. No.:
9/521144
Inventors:
Jill M. Lahti - Cordova TN
Vincent J. Kidd - Cordova TN
Vincent J. Kidd - Cordova TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12N 1500
C12N 506
C07K 100
C12P 2108
C12N 506
C07K 100
C12P 2108
US Classification:
4353201
Abstract:
The present invention includes alternatively and partially spliced cyclin C mRNAs, recombinant DNA and the truncated protein (a truncated cyclin C) they encode. The alternatively spliced mRNAs result from an insertion of unique exons containing premature termination codons. The partially spliced mRNAs result from an insertion of additional coding sequence derived from exons. One aspect of the present invention is the demonstration that at least one of the alternatively spliced cyclin C mRNAs is produced in a cell cycle dependent fashion, as is the novel truncated cyclin box protein that it encodes. Truncated cyclin C acts as an endogenously encoded cyclin C inhibitor by negatively regulating cyclin C/cdk8 complex activity, in much the same way as the cyclin dependent protein kinase inhibitors that inhibit the D-type cyclins, cyclin A and cyclin E.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.